Cytek Biosciences (CTKB) Accumulated Expenses (2020 - 2026)

Cytek Biosciences' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $19.8 million for Q1 2026.

• Quarterly Accumulated Expenses rose 3.04% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 million (up 3.04% YoY) and the FY2025 annual result came in at $23.4 million, up 9.21% from the prior year.
• Accumulated Expenses was $19.8 million for Q1 2026 at Cytek Biosciences, down from $23.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $23.4 million in Q4 2025 and bottomed at $14.6 million in Q1 2022.
• A 5-year average of $19.5 million and a median of $20.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 54.72% — and 2024, when it declined 20.94%.
• Cytek Biosciences' Accumulated Expenses stood at $21.1 million in 2022, then fell by 5.16% to $20.0 million in 2023, then gained by 7.03% to $21.4 million in 2024, then rose by 9.21% to $23.4 million in 2025, then slipped by 15.53% to $19.8 million in 2026.
• Business Quant data shows CTKB's Accumulated Expenses at $19.8 million in Q1 2026, $23.4 million in Q4 2025, and $20.2 million in Q3 2025.